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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is the
use of laser therapy an effective alternative treatment for women with fibromyalgia?”
STUDY DESIGN: Review of three English language primary studies, published between 2002
and 2013.
DATA SOURCES: Three randomized controlled trials (RCTs) were found using Cochrane
Systematic Reviews. These studies analyzed the effectiveness of laser therapy in women with
fibromyalgia.
OUTCOMES MEASURED: Main outcomes measured were improvement in pain, number of
tender points, muscular spasm, skinfold tenderness, sleep disturbance, fatigue and morning
stiffness measured by an ordinal likert scale, Pain and FM impact measured by the FM Impact
Questionnaire (FIQ), Body flexibility measured by the continuous scale physical functional
performance test (CS-PFP), number of tender points measured by distal palpation, and well
being measured by the verbal scale of global evaluation by the patient concerning her well-being
(VSGI). P-values were used to assess the significance of the outcomes.
RESULTS: All three studies showed significant improvement in the functioning of women with
fibromyalgia. In the Panton et all study, it was shown that there were improvements in pain,
upper body flexibility, and FM impact. The Gur et all study showed improvements in pain,
muscle spasm, morning stiffness, and total tender point number, and the Armagan et al study
showed improvements in the FIQ, VSGI, and total myalgia after laser therapy.
CONCLUSION: The results of three RCTs which compared before and after laser treatment
groups to before and after placebo laser therapy groups showed laser therapy to be an effective
treatment for women with fibromyalgia.
KEY WORDS: Fibromyalgia, Laser therapy.
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INTRODUCTION
Fibromyalgia is a rheumatologic disorder characterized mainly by widespread chronic
body pain.5 The American College of Rheumatology goes on to define the diagnosis as pain in
three out of four of the body quadrants for at least a duration of three consecutive months as well
as tenderness with palpation at eleven or more out of eighteen of specific tender points.5
Although pain is the most common complaint, fibromyalgia patients commonly report insomnia,
fatigue, headaches, irritable bowel syndrome, morning stiffness, parenthesias, anxiety, and
depression.1
Fibromyalgia is considered the second most common rheumatologic disorder in the
United States in that it is found in approximately four to six million people.5 In total, it is said to
affect about 3% of the female population but it has also been found to occur in both men and
children.1 Additionally, women tend to be diagnosed with the disorder between the ages of 20
and 50 but the prevalence does increase with age.5 By the age of 80, 8% of women are diagnosed
with fibromyalgia.5
Due to the commonality of the disorder, there is a definite economic burden in the United
States due to heath care costs pertaining to fibromyalgia patients. The total annual cost to the
United States economy is twelve to fourteen billion dollars.7 In addition, 34% of all fibromyalgia
patients tend to spend between $100 and $1,000 per month above what their insurance will cover
in order to be seen and treated by a healthcare professional in their times of need.5 The average
fibromyalgia patient a goes to see a healthcare professional thirteen times per year.6
Although fibromyalgia is a rather common disorder, research has yet to discover the
exact cause leading to its development. It is, however, thought that central sensitization is the
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main mechanism involved, as well as many other components such as genetic predisposition,
environmental stressor exposure, alterations in sleep architecture, hypothalamic-pituitary adrenal
axis alterations, and autonomic nervous systems alterations. Genetics are thought to be involved
in the disorder because there is a strong familial link. Patients with the diagnosis had an eight
times greater chance of a first-degree relative having the diagnosis as well. The environmental
triggers that are thought to be involved are a prior history of trauma or abuse, as well as infection
and psychological stress. In terms of alteration of the sleep cycle, it is thought that patients with
fibromyalgia are experiencing intermittent arousal from the brain, leading to constant
interruption of their deepest and most refreshing sleep. Lastly, the hypothalamic-pituitaryadrenal axis and autonomic nervous systems alterations seem to play a role in the development
of the disorder because studies have shown that patients have a higher heart rate at rest as well as
less variability in their heart rate throughout the day.7
In addition to the multiple contributing factors to the development of fibromyalgia, there are
also multiple modalities used for treatment and comfort in patients with fibromyalgia. Firstly, the
typical pharmacologic interventions utilized are tricyclic antidepressants, serotonin antagonists,
nonsteroidal anti-inflammatory drugs, anti-epileptic drugs, sedatives, muscle relaxants, and opiates.5
Secondly, alternative interventional techniques such as trigger point injections, massage therapy,
exercise, physical therapy, electrotherapy, and biofeedback training have also been used in
treatment.1 Typically, patients will use multiple management techniques in order to control their pain
level as much as possible.1
While these treatments have been shown to somewhat alleviate the pain, their use for
treatment has been limited and there is currently no complete cure for the condition.1 It has been
shown that pharmacologic therapy has achieved successful improvement in only 50% of patients, as
well as leading to many side-effects such as weight gain, morning drowsiness, abdominal pain, and
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increased tolerance to the treatment overtime.5 It is also shown that 47% of the women with
fibromyalgia are nonadherent with their medications.5 For these reasons, alternative interventions
such as laser therapy have shown an increase in popularity among patients and may be used to help
relieve the symptoms of fibromyalgia.5
OBJECTIVE
The objective of this selective EBM review is to determine whether or not, “Is the use of
laser therapy an effective alternative treatment for women with fibromyalgia?”
METHODS
The population of the studies used for this review includes women with fibromyalgia. Their
ages ranged from 33 to 64. One of the studies involved in the review used class IV laser therapy, one
used class III b laser therapy, and the other one used low-level energy laser therapy. The comparison
groups were given sham laser therapy that was a visually matched placebo. The different outcomes
measured in the studies included improvement in pain, number of tender points, muscular spasm,

skinfold tenderness, sleep disturbance, fatigue, morning stiffness, FM impact, body flexibility,
and well-being. All three studies were randomized controlled trials that compared laser therapy to
placebo laser therapy.
The author, using the key words “fibromyalgia” and “laser therapy, carried out a detailed
search using the Cochrane Systematic Review and PubMed. Each of the articles was published in
English and in peer-reviewed journals. Each of the articles was selected based on their relevance to
the clinical question as well as their evidence falling in the category of a POEM. Inclusion criteria
consisted of articles that involved randomly controlled trials published after 2000. Studies excluded
were those that involved male participants. The statistic that was reported in the three studies was a
p-value with a p ≤ .05 deemed statistically significant. Table 1 displays the demographics and
characteristics of these three articles.
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Table 1: Demographics & Characteristics of included studies
Study

Type

#pts

Age
(yrs)
52
±11
yrs

(Panton)5
2013

Double
blind
RCT

38

(Gur)2
2002

Single
blind
RCT

40

40
±15
yrs

(Armagen)
1
2006

Single
blind
RCT

32

38.94
± 4.85

Inclusion
criteria
Female
At least 11
out of 18
tender
points.

Exclusion criteria

Uncontrolled
hypertension/ DM,
Active heart disease,
history of cancer, Long
term steroid use,
Pregnant, Endocrine
disease, anticoagulation,
bleeding disorders,
stroke, chronic infection,
malignancy, taking
medication that causes
photosensitivity,
contraindication to light
or thermal therapy, under
the care of a chiropractic
physician, acupuncture
physician, massage
therapist, or other forms
of manual therapy.
Female
A recent or past history
At least 11 of psychiatric disorders,
out of 18
Immunocompromised
tender
subjects, Subjects with
points
neurological,
Widespread inflammatory, endocrine
pain for 3
or clinically, significant
months
chronic disease,
Abnormal liver function
tests, Pregnancy
Female
Inflammatory cause of
Widespread pain; Inability to interrupt
pain for at
therapy with analgesic,
least 3
anti-inflammatory
months on
medications,
both sides
antidepressants, sleeping/
of body,
central nervous systemabove and
active
below the
drugs;neurological,
waist.
inflammatory, endocrine,
At least 11 or chronic disease, such
tender
as IBD, rheumatoid
points
arthritis, lupus, or DM;
Severe disease such as a
tumor, liver, renal
disease; Pregnancy;
major psychiatric
disorders.

W/D

Interventions

3

Class IV laser
therapy

0

Low power laser
therapy

0

Low level laser
therapy
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OUTCOMES MEASURED
Each outcome measured was a POEM and was measured in a variety of ways. Firstly,
Gur et al measured the outcomes of improvement in pain, number of tender points, skinfold
tenderness, morning stiffness, sleep disturbance, muscular spasm, and fatigue using an ordinal
likert scale. The categories on the scale were, No (0), moderate (1), severe (3), and extreme (4).
Panton et al used multiple methods to measure the chosen outcomes of tender-point
sensitivity, the Fibromyalgia Impact Questionnaire (FIQ), and functionality. Firstly, at the
participants initial visit as well as after their four week long treatment, they had a tender points
assessment performed by a rheumatologist who then decided on their number of tender points, as
well as rating those points on a sensitivity scale from 0, meaning no pain, to 3, meaning
withdrawal of patient from examiner. The FM Impact Questionnaire (FIQ) was also used as an
outcome to measure the impact that the disorder had on their quality of life. The FIQ is able to
measure physical functioning in activities of daily living, general-well being of the patient, as
well as fibromyalgia related-symptoms like pain and body flexibility. Lastly, the Continuous
Scale Physical Functional Performance (CS-PFP) test was used revealing the participant’s level
of physical functioning. This test simulates different tasks of common daily activities. At the
completion of the four-week intervention, participants repeated the testing that was completed in
the initial visit again. The investigators who measured tender-point sensitivity, FIQ, and
functionality were blinded to the group assignment of the participants.5
Lastly, Armagen et al used multiple methods to study their outcomes as well. Number of
tender points was measured using digital palpation. The point was recorded as tender if the
patient reported it upon palpation. Morning stiffness was measured using an ordinal Likert scale
defined as no (0), mild (1), moderate (2), severe (3), and extreme (4). This study also used the
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Fibromyalgia Impact Questionnaire (FIQ) and the Verbal scale of global evaluation by the
patient concerning her well-being (VSGI). The VSGI created a score from 1 to 5 in which 1
means great improvement, 2 means moderate improvement, 3 means slight improvement, 4
means no improvement, and 5 means worsening. A Total myalgia score was then created through
response to a digital force of 4 kg after which the participants said whether they felt no
discomfort (0 points), tenderness (1 point), pain without grimace, flinching, or withdrawal (2
points), or pain with grimace, flinching, or withdrawal (3 points).1
RESULTS
Armagon et al included 32 female patients ages 26 to 47 in the trial. All 32 of them
carried out the entirety of the study. All patients received treatments once a day, five days a
week, for a total duration of ten days. The laser beam was applied to each tender point for one
minute and the same physician treated all of the patients. All of the patients in the study, whether
in the laser treatment or placebo group, had similar conditions prior to treatment. In the laser
treatment group, participants showed significant improvements in all categories measured after
laser therapy. Tender point number decreased by an average of 1.87, morning stiffness decreased
by an average of .62, VSIQ score decreased by an average of .88, FIQ scores decreased by an
average of 7, and total myalgia scores decreased by an average of 5.5. For these scores, P < 0.05.
On the contrary, the only categories in which significant improvement could be seen in those
treated with placebo laser therapy were number of tender points and morning stiffness. Tender
point number decreased by an average of 1.06 and morning stiffness decreased by an average of
.56. In these two categories, P < 0.05. These results can be seen in table 2. There were no
systemic or local side effects that were reported during or after the treatment period in either
group of participants.1
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Table 2: Mean	
  change	
  from	
  baseline, Armagon et al 1
Tender
points

Morning
stiffness

VSIQ score

FIQ score

Total
Myalgia

Laser
therapy

-1.87*

-.62*

-.88*

-7*

-5.5*

Sham laser
therapy

-1.06*

-.56*

-.19

-1.75

-1.56

* p <.05
Gur et all included 40 females with fibromyalgia. All patients carried out the entirety of
the study. Each patient experienced a two-week treatment period of five days per week for a total
of ten treatments. The laser therapy included three minutes of treatment on each tender point.
Prior to the treatment, the two groups showed no significant difference in any of the categories
studied when compared to each other. However, significant changes in all categories were seen
in those participating in the actual laser therapy group. Pain improved by an average of 1.82,
skinfold tenderness improved by an average of 1.28, muscle spasm improved by an average of
1.46, morning stiffness improved by an average of 1.45, tender point number improved by an
average of 6.55, sleep disturbance improved by an average of 1.09, and fatigue improved by an
average of 1.73. For these values p<0.05. On the contrary, the placebo group only showed
significant improvement in pain, muscle spasm, morning stiffness, and tender point number. Pain
improved by an average of 1.0, muscle spasm improved by an average of .9, morning stiffness
improved by an average of .69, tender point number improved by an average of 4.15. For these
values p<0.05. These results are shown in table 3. None of the participants in the study reported
increased discomfort as a result of their treatment or an increase in any of the measured
outcomes, whether they received the laser or the placebo therapy.2
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Table 4. Mean	
  change	
  from	
  baseline,	
  Gur	
  et	
  al2	
  
	
  

Pain

Skinfold
tenderness

Muscle
spasm

Morning
stiffness

Tender
points

Sleep
disturbance

Fatigue
	
  

Laser
therapy

-1.82*

-1.28*

-1.46*

-1.45*

-6.55*

-1.09*

-1.73*

Sham laser
therapy

-1.0*

-.77

-.9*

-.69*

-4.15*

-.04

-.06

*p <.05
The Panton et al study included 42 women with fibromyalgia, 38 of whom completed the
entirety of the study. One woman did not follow up after the initial assessments, two women did
not return due to scheduling conflict, and a final woman could not complete the study due to
major depressive disorder. In order for this study to make the two groups appear to have the
same treatment, the treatment group was given laser and heat therapy, while the placebo group
was given sham and heat therapy. Both groups had treatment twice each week for four weeks,
totaling in eight treatments. When looking at the baseline statistics alone, the treatment and
control groups did not significantly differ. Of the different outcomes measured in the laser and
heat therapy group, significant improvement resulted in total tender points, myalgic score, pain,
upper body flexibility, and the CS-PFP score. Total tender points decreased by an average of 3,
myalgic score decreased by an average of 3, pain decreased by an average of .9, upper body
flexibility increased by an average of 7, and CS-PFP score increased by an average of 7. In order
to show significance in these numbers, p<0.05. On the other hand, the group that received sham
and heat treatment showed significant changes in only the number of tender points, myalgic
score, and CS-PFP score. Number of tender points decreased by an average of 3, myalgic score
decreased by an average of 3, and CS-PFP scores increased by an average of 4. These results
can be seen in table 5.5
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Table 5. Mean change from baseline, Panton et al5
Tender
points

Myalgic
score

Pain

Upper body
flexibility

CS-PFP

Laser
therapy

-3*

-3*

-.9*

7*

7*

Sham laser
therapy

-3*

-3*

.3

0

-4*

* p <.05
DISCUSSION
The three randomized controlled trials discussed in this review suggest that laser therapy
is an effective alternative treatment for fibromyalgia. All three studies demonstrated a
statistically significant reduction in at least two of the outcomes measured with a statistical
significance threshold set at p ≤ .05. One other study conducted by Gur et al compared laser
therapy to sham laser therapy as well as the traditionally used Amytriptyline. This study showed
that the laser therapy was above all else in terms of decreasing pain intensity, fatigue, morning
stiffness, FIQ score, and depression score, which shows great promise for the use of laser therapy
in fibromyalgia treatment.1
The Panton et al study showed the least positive difference when comparing the
experimental and control groups, but there are a few possible explanations for this contradiction
to the other two studies. This study decided that in order to make the control and experimental
groups similar enough, both groups would require heat application to the treated area. Since heat
has been shown to have some therapeutic properties in the treatment of fibromyalgia, this would
explain the improvement in the outcomes of the control group. However, since the women that
received the laser as well as heat therapy showed additional positive outcomes as well as a
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greater difference in the outcomes when compared to the control group, this study still suggests
that laser therapy is an effective alternate treatment for fibromyalgia.5
On the other hand, it is important to note that there are still many limitations regarding
laser therapy as a treatment mechanism in that literature laser treatment has been inconsistent and
disorganized.2 Information surrounding the specificities of the laser treatment parameters such as
the optimal dose, intensity, frequency, wavelength, and peak that should be used, as well as the
best mode of delivery, is still unknown.1 There are also different treatment techniques such as
irradiating one single point or sweeping across it. One technique has not yet been shown to be
more effective than the others.2 Additionally, it is unknown if certain parameters must be altered
based on the specific areas to be irradiated and diagnosis of the person being treated. These
parameters could include the minimally effective dose, duration, number, and schedule of the
treatment.1 The different bodily tissues on the body may have different absorption spectra and
could respond in a different manner to the laser.2 As a result of these various unknowns about the
use of laser therapy as a treatment method, further clinical evaluation and research is needed.
Research is also needed to provide information on when the treatment should be terminated and
how long the benefits will last.
Laser therapy continues to be used for treatment in many disciplines. The FDA has
approved the usage of low-level laser therapy, however, there are some contraindications to its
usage.3 Currently, known contraindications include a history of malignant carcinoma, radiation
in the thyroid region, epilepsy, exposure of the retina during treatment, and pregnancy.4
Additionally, most insurance companies do not typically cover laser therapy, but as research on
its treatment for fibromyalgia continues, there is hope of future coverage for patients.3
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CONCLUSION
Laser therapy is an effective treatment alternative for women with fibromyalgia.
The three randomized controlled trials discussed in this review showed improvement in
outcomes measured after the application of laser therapy. Based on these results, low-level laser
therapy should be considered as monotherapy or as an additional supplement to other treatment
modalities in women with fibromyalgia.
Despite this convincing evidence, additional research needs to be done in order to answer
questions about the best treatment protocol in terms of scheduling, wavelength, frequency, and
intensity, as well as deducing whether different areas of a patient’s body will require different
protocols. Additional research should also be completed to compare currently used therapeutic
treatment regimens to the laser therapy, as well as comparing whether monotherapy or
polytherapy would be most cost effective. Lastly, additional research is needed to decide if there
are long-term benefits to each laser therapy treatment or if the laser treatments will have to be
continued on a life-long basis.
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